ClinicalTrials.gg

Program

HR17031

A development code. Also written as “HR17031 injection” and “HR17031 injection ;INS068 injection;SHR20004 injection”.

Its studies are mostly in Diabetes Mellitus, Type 2, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Feb 26, 20257 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine70 open or runningphase 3since Feb 26, 2025Aug 16, 2021none ahead
  • Named in Jiangsu HengRui Medicine’s own pipeline as HR17031, phase 4, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 16, 2021First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT05031871 · 24 enrolled · China
  2. Dec 7, 2021Phase 1 study in Improved Glycemic Control in Patients With Type 2 DiabetesNCT05151705 · 24 enrolled
  3. Mar 15, 2022Phase 1 study in Improved Glycemic Control in Patients With Type 2 DiabetesNCT05292495 · 24 enrolled · China
  4. Apr 12, 2022Phase 2 study in Diabetes Mellitus, Type 2NCT05333835 · 455 enrolled · China
  5. Oct 12, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT06086912 · 24 enrolled · China
  6. Feb 26, 2025Phase 3 study in Adult Patients With Type 2 DiabetesNCT06871761 · 393 enrolled · China
  7. Mar 12, 2025Phase 3 study in Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic DrugsNCT06881264 · 401 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06881264Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs · China3CompletedSep 19, 2025401
NCT06871761Adult Patients With Type 2 Diabetes · China3CompletedMay 13, 2025393
NCT06086912Diabetes Mellitus, Type 2 · China1CompletedDec 12, 202324
NCT05333835Diabetes Mellitus, Type 2 · China2UNKNOWNMar 30, 2024455
NCT05292495Improved Glycemic Control in Patients With Type 2 Diabetes · China1CompletedApr 10, 202424
NCT05151705Improved Glycemic Control in Patients With Type 2 Diabetes1UNKNOWNJun 15, 202224
NCT05031871Diabetes Mellitus, Type 2 · China1CompletedNov 19, 202124

How it is read

Names in the registry

  • “HR17031 injection”, 7 entries
  • “HR17031 injection ;INS068 injection;SHR20004 injection”, 4 entries
  • “HR17031”, 3 entries

Codes read as this program: HR17031.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.